Emergent Travel Health

48 articles about Emergent Travel Health

• 

  Mosquitoes Will Rule the Earth as Climate Change Expands Disease Vectors

  9/26/2018

  Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
• 

  Emergent BioSolutions Acquires Adapt Pharma in $735 Million Deal

  8/29/2018

  Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in cash for various sales-based milestones through 2022.
• 

  Here's Five Vaccines to Keep Your Eye on

  8/15/2018

  On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that ...
• 

  Emergent BioSolutions Buys PaxVax for $270 Million

  8/10/2018

  Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.

• Emergent BioSolutions to Acquire PaxVax from Cerberus Capital Management

  8/9/2018

  Combined company will capitalize on PaxVax's robust pipeline, proven commercial track record, and validated scientific and clinical acumen

• FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine

  5/4/2018

  - Fast Track program is designed to facilitate development and expedite review of therapies and vaccines to address unmet health needs - There are no licensed vaccines for chikungunya prevention and no specific treatments

• PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine

  4/25/2018

  There are currently no licensed vaccines to prevent chikungunya and no specific treatments for the complications of the infection.

• PaxVax's Randomized Placebo-Controlled Study Provides Encouraging Results for a Higher Dose Formulation of Vaxchora (CVD 103-HgR) as a Potential Tool in Containing Cholera Epidemics

  12/6/2017

  Results support potential future development of a new formulation of Vaxchora as an important additional tool for global cholera control in developing countries.

• PaxVax, Inc. Release: CDC Recommends that Adults Traveling To Cholera-Affected Destinations Get Vaccinated With Vaxchora (Cholera Vaccine, Live, Oral)

  5/12/2017

• PaxVax, Inc. Initiates Clinical Trials Of A Modernized Adenovirus Vaccine In Collaboration With The U.S. Army Medical Materiel Development Activity And The Walter Reed Army Institute Of Research To Protect U.S. Military Personnel

  5/8/2017

• PaxVax, Inc. Partners With NIH And Department Of Defense To Develop A New Virus-Like Particle Vaccine To Fight The Spread Of Chikungunya

  1/5/2017

• PaxVax, Inc.'s Vaxchora Now Available As The Only U.S. Approved Vaccine For Protection Against Cholera

  10/24/2016

• PaxVax, Inc. To Receive California Life Sciences Association's 2016 Rising Star Award

  10/11/2016

• PaxVax, Inc. CEO Nima Farzan Joins Board Of The Coalition For Epidemic Preparedness Innovations

  9/21/2016

• LEUKOCARE Grants License To US Vaccine Company PaxVax, Inc.

  9/13/2016

• Specialty Vaccine Company PaxVax, Inc. Appoints Philip K. Moody As Chief Financial Officer

  9/6/2016

• PaxVax, Inc. Inks Swiss Marketing And Distribution Agreement With Seqirus For Influenza Vaccines

  8/29/2016

• CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax, Inc.’s Single-Dose Oral Cholera Vaccine

  6/23/2016

• FDA Approves PaxVax, Inc. To Manufacture Vaxchora (Oral Cholera Vaccine) At SynCo Bio Partners B.V.

  6/20/2016

• FDA Approves Vaxchora, PaxVax, Inc.’s Single-Dose Oral Cholera Vaccine

  6/13/2016